

**Utilizing Real World Evidence: Focus on Multiple Myeloma
in Older Adults – Tweakorial #1**

References

Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. *Leukemia*. 2020;34(7):1875-1884. doi:10.1038/s41375-020-0711-6

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8

Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;375(14):1319-1331. doi:10.1056/NEJMoa1607751

Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. *Br J Haematol*. 2017;177(3):404-413. doi:10.1111/bjh.14549

Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet*. 2017;389(10068):519-527. doi:10.1016/s0140-6736(16)31594-x

Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. *Leukemia*. 2020;34(1):224-233. doi:10.1038/s41375-019-0539-0

Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021;22(11):1582-1596. doi:10.1016/s1470-2045(21)00466-6

Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Blood*. 2021;137(26):3616-3628. doi:10.1182/blood.2020008787

Gavriatopoulou M, Terpos E, Dimopoulos MA. The extended 4-year follow-up results of the ELOQUENT-2 trial. *Oncotarget*. 2019;10(2):82-83. doi:10.18632/oncotarget.26527

Hungria V, Beksac M, Weisel KC, et al. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. *Br J Haematol*. 2021;193(3):561-569. doi:10.1111/bjh.17321

NINLARO® (ixazomib). Prescribing information. Takeda Pharmaceuticals. March 2021.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208462s010lbl.pdf

Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol*. 2020;21(10):1317-1330. doi:10.1016/s1470-2045(20)30452-6

Lee HC, Ailawadhi S, Gasparetto CJ, et al. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry. *Blood Cancer J*. 2021;11(7):134. doi:10.1038/s41408-021-00524-1

Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med*. 2015;373(7):621-631. doi:10.1056/NEJMoa1505654

Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. *Clin Lymphoma Myeloma Leuk*. 2020;20(8):509-518.
doi:10.1016/j.clml.2019.09.623

Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;374(17):1621-1634. doi:10.1056/NEJMoa1516282

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma (v4.2022). Updated December 14, 2021. Accessed December 23, 2021.
https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5(6):649-55.

Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood*. 2015;125(13):2068-2074.
doi:10.1182/blood-2014-12-615187

Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;375(8):754-766. doi:10.1056/NEJMoa1606038

Plesner T, Dimopoulos MA, Oriol A, et al. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. *Br J Haematol*. 2021;194(1):132-139. doi:10.1111/bjh.17435

Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 Phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. *J Clin Oncol*. 2021;39(22):2430-2442. doi:10.1200/JCO.21.00972

SEER. Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD. Accessed December 20, 2021. <https://seer.cancer.gov/statfacts/html/mulmy.html>

Stewart AK, Dimopoulos MA, Masszi T, et al. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. *J Clin Oncol*. 2016;34(32):3921-3930. doi:10.1200/JCO.2016.66.9648

Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2015;372(2):142-152. doi:10.1056/NEJMoa1411321

Zhou L, Yu Q, Wei G, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. *BMC Cancer*. 2021;21(1):606. doi:10.1186/s12885-021-08280-y

Glossary

AE, adverse event
AIDS, acquired immunodeficiency syndrome
ADL, Activities of Daily Living
CCI, Charlson Comorbidity Index
CI, confidence interval
CRR, complete response rate
d, dexamethasone
D, daratumumab
DRd, daratumumab/lenalidomide/dexamethasone
DVd, daratumumab/bortezomib/dexamethasone
ECOG, Eastern Cooperative Oncology Group
EloRd, elotuzumab/lenalidomide/dexamethasone
GHS, global health status
HR, hazard ratio
IADL, Instrumental Activities of Daily Living
IMD, immunomodulatory drugs
IMWG, International Myeloma Working Group
I, ixazomib
IRd, ixazomib/lenalidomide/dexamethasone
K, carfilzomib
KRd, carfilzomib/lenalidomide/dexamethasone
LSMD, least squares mean difference
MACE, major adverse cardiovascular event
MM, multiple myeloma
mOS, median overall survival
mPFS, median progression-free survival
NCCN, National Comprehensive Cancer Network
NDMM, newly diagnosed multiple myeloma
NR, not reported
OS, overall survival
ORR, overall response rate
PFS, progression-free survival
PI, proteasome inhibitor
PS, performance status
QOL, quality of life
R, lenalidomide
Rd, lenalidomide/dexamethasone
RRMM, relapsed/refractory multiple myeloma
V, bortezomib
Vd, bortezomib/dexamethasone
VRd, bortezomib/lenalidomide/dexamethasone